Security
Olema Pharmaceuticals, Inc. Common Stock · OLMA
OLMANASDAQCommon stockCurrentCIK 1750284Updated Oct 19, 2026
OLMA price & chart
Loading TradingView…
NASDAQ:OLMA on TradingView ↗About the company
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
In the news
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ↗
Biotech Stocks Rally as Oncology Market Targets $866B by 2034 News provided by Equity Insider Aug 14, 2025, 12:30 ET Share this article Share to X Share this article Share to X Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Aug. 14, 2025 /PRNewswire/ -- E ↗
Seeking Alpha
Olema Pharmaceuticals, Inc. (OLMA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript ↗
Olema drops after hours on AstraZeneca Etcamah data ↗
Olema Pharmaceuticals, Inc. (OLMA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript ↗
SEC disclosures
Olema Pharmaceuticals, Inc. files 8-K: Material Event ↗
Recent filings
SCHEDULE 13D/A - filed by BIOTECHNOLOGY VALUE FUND L P regarding Olema Pharmaceuticals, Inc.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 352,453,000Source | 230,173,000Source | 486,578,000Source | 382,002,000Source | 254,557,000Source | 530,645,000Source | 409,639,000Source | 263,694,000Source | 533,430,000Source | 450,979,000Source | 276,945,000Source | 215,645,000Source |
| Property, Plant and Equipment, NetUSD | 486,000Source | 849,000Source | 382,000Source | 560,000Source | 945,000Source | 356,000Source | 653,000Source | 1,033,000Source | 274,000Source | 746,000Source | 968,000Source | 1,480,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 35,260,000Source | 35,888,000Source | 48,599,000Source | 52,473,000Source | 16,892,000Source | 52,547,000Source | 50,640,000Source | 33,720,000Source | 48,301,000Source | 139,480,000Source | 68,539,000Source | 23,702,000Source |
| Assets, CurrentUSD | 334,329,000Source | 217,994,000Source | 469,876,000Source | 367,725,000Source | 242,187,000Source | 513,229,000Source | 396,663,000Source | 252,090,000Source | 515,452,000Source | 438,473,000Source | 266,513,000Source | 208,899,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,369,000Source | 3,231,000Source | 8,806,000Source | 5,812,000Source | 3,083,000Source | 7,882,000Source | 3,956,000Source | 3,113,000Source | 10,015,000Source | 4,387,000Source | 4,706,000Source | 4,478,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,419,000Source | 1,567,000Source | 638,000Source | 1,685,000Source | 1,814,000Source | 921,000Source | 1,055,000Source | 2,055,000Source | 1,146,000Source | 1,314,000Source | 2,291,000Source | 2,495,000Source |
| Other Assets, NoncurrentUSD | — | 15,000Source | — | 15,000Source | 16,000Source | — | 14,000Source | — | — | 15,000Source | — | 2,771,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 44,965,000Source | 31,262,000Source | 56,014,000Source | 36,766,000Source | 27,394,000Source | 50,167,000Source | 26,187,000Source | 27,376,000Source | 54,871,000Source | 42,015,000Source | 23,050,000Source | 18,099,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 7,000Source | 4,000Source | 8,000Source | 7,000Source | 4,000Source | 8,000Source | 7,000Source | 4,000Source | 8,000Source | 6,000Source | 4,000Source | 3,000Source |
| Additional Paid in CapitalUSD | 858,451,000Source | 599,982,000Source | 1,145,349,000Source | 854,194,000Source | 594,261,000Source | 1,131,576,000Source | 848,520,000Source | 572,926,000Source | 1,075,487,000Source | 843,921,000Source | 559,176,000Source | 408,333,000Source |
| Retained Earnings (Accumulated Deficit)USD | -551,496,000Source | -401,539,000Source | -713,846,000Source | -509,279,000Source | -366,984,000Source | -650,646,000Source | -465,495,000Source | -336,602,000Source | -597,557,000Source | -435,106,000Source | -305,632,000Source | -208,977,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 526,000Source | 464,000Source | -947,000Source | 314,000Source | -118,000Source | -460,000Source | 420,000Source | -10,000Source | 621,000Source | 143,000Source | 347,000Source | -1,813,000Source |
| Stockholders' Equity Attributable to ParentUSD | 307,488,000Source | 198,911,000Source | 430,564,000Source | 345,236,000Source | 227,163,000Source | 480,478,000Source | 383,452,000Source | 236,318,000Source | 478,559,000Source | 408,964,000Source | 253,895,000Source | 197,546,000Source |
| Liabilities and EquityUSD | 352,453,000Source | 230,173,000Source | 486,578,000Source | 382,002,000Source | 254,557,000Source | 530,645,000Source | 409,639,000Source | 263,694,000Source | 533,430,000Source | 450,979,000Source | 276,945,000Source | 215,645,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 41,655,000Source | 30,700,000Source | 53,014,000Source | 33,164,000Source | 26,535,000Source | 47,167,000Source | 26,064,000Source | 26,224,000Source | 51,802,000Source | 41,758,000Source | 21,621,000Source | 16,549,000Source |
| Operating Lease, Liability, CurrentUSD | 1,168,000Source | 1,137,000Source | 660,000Source | 1,153,000Source | 1,103,000Source | 956,000Source | 1,025,000Source | 1,057,000Source | 1,124,000Source | 1,172,000Source | 988,000Source | 1,015,000Source |
| Accounts Payable, CurrentUSD | 3,474,000Source | 2,685,000Source | 1,667,000Source | 934,000Source | 4,354,000Source | 3,719,000Source | 151,000Source | 7,656,000Source | 9,253,000Source | 4,460,000Source | 2,698,000Source | 374,000Source |
| Operating Lease, Liability, NoncurrentUSD | 310,000Source | 562,000Source | 0Source | 602,000Source | 859,000Source | 0Source | 123,000Source | 1,152,000Source | 69,000Source | 257,000Source | 1,429,000Source | 1,550,000Source |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 329,000,000Source | 214,800,000Source | 461,100,000Source | 361,900,000Source | 239,100,000Source | 505,300,000Source | 392,700,000Source | 249,000,000Source | 505,400,000Source | 434,100,000Source | 261,800,000Source | 204,400,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -53,089,000Source | -30,389,000Source | -162,451,000Source | -129,474,000Source | -96,655,000Source | -104,787,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 119,000Source | 128,000Source | 490,000Source | 393,000Source | 377,000Source | 357,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 10,148,000Source | 4,378,000Source | 17,586,000Source | 22,582,000Source | 17,256,000Source | 18,829,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -5,681,000Source | -4,309,000Source | 4,598,000Source | 2,510,000Source | 2,324,000Source | 351,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -45,987,000Source | -43,979,000Source | -146,716,000Source | -104,351,000Source | -83,727,000Source | -82,065,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 4,529,000Source | -45,083,000Source | -155,760,000Source | -93,526,000Source | -4,851,000Source | 91,479,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | 159,000Source | — | 363,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 45,704,000Source | 222,000Source | 211,297,000Source | 268,818,000Source | 133,415,000Source | 476,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 4,246,000Source | -88,840,000Source | -91,179,000Source | 70,941,000Source | 44,837,000Source | 9,890,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 35,260,000Source | 35,888,000Source | 48,599,000Source | 52,473,000Source | 52,547,000Source | 50,640,000Source | 48,301,000Source | 139,480,000Source | 68,539,000Source | 23,702,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 4,250,000Source | 5,626,000Source | 12,903,000Source | 4,692,000Source | 10,148,000Source | 4,378,000Source | 17,586,000Source | 22,582,000Source | 17,256,000Source | 18,829,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 329,000,000Source | 214,800,000Source | 461,100,000Source | 361,900,000Source | 505,300,000Source | 392,700,000Source | 505,400,000Source | 434,100,000Source | 261,800,000Source | 204,400,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | — | -9,000Source | -111,000Source | — |
| General and Administrative ExpenseUSD | — | — | 5,926,000Source | 4,395,000Source | 9,394,000Source | 3,962,000Source | 8,754,000Source | 4,249,000Source | 21,001,000Source | 17,741,000Source | 18,821,000Source | 24,714,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 3,000Source | 2,000Source | 2,000Source | 1,000Source |
| Investment Income, InterestUSD | — | — | 3,648,000Source | 2,928,000Source | 4,507,000Source | 4,042,000Source | 4,776,000Source | 4,524,000Source | 16,224,000Source | 12,682,000Source | 8,325,000Source | 2,228,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -42,217,000Source | -34,555,000Source | -63,200,000Source | -43,784,000Source | -53,089,000Source | -30,389,000Source | -162,451,000Source | -129,474,000Source | -96,655,000Source | -104,787,000Source |
| Nonoperating Income (Expense)USD | — | — | 3,660,000Source | 3,066,000Source | 3,979,000Source | 4,080,000Source | 4,897,000Source | 4,484,000Source | 16,247,000Source | 12,784,000Source | 8,306,000Source | 2,201,000Source |
| Operating ExpensesUSD | — | — | 45,877,000Source | 37,621,000Source | 67,179,000Source | 47,864,000Source | 57,986,000Source | 34,873,000Source | 178,698,000Source | 142,258,000Source | 104,961,000Source | 106,988,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 12,000Source | 138,000Source | -528,000Source | 38,000Source | 121,000Source | -40,000Source | 23,000Source | 102,000Source | -19,000Source | -27,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 8,430,000Source | 236,000Source | 8,391,000Source | 1,671,000Source | 2,629,000Source | 146,000Source |
| Payment, Tax Withholding, Share-based Payment Arrangement | — | — | — | — | — | — | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -45,877,000Source | -37,621,000Source | -67,179,000Source | -47,864,000Source | -57,986,000Source | -34,873,000Source | -178,698,000Source | -142,258,000Source | -104,961,000Source | -106,988,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 12,000Source | 138,000Source | -528,000Source | 38,000Source | 121,000Source | -40,000Source | 23,000Source | 102,000Source | -19,000Source | -27,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -162,448,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 3,000Source | 2,000Source | 2,000Source | 1,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -42,217,000Source | -34,555,000Source | -63,200,000Source | -43,784,000Source | -53,089,000Source | -30,389,000Source | -162,451,000Source | -129,474,000Source | -96,655,000Source | -104,787,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.49Source | -0.6Source | -0.61Source | -0.51Source | -0.52Source | -0.36Source | -1.87Source | -2.2Source | -2.14Source | -2.62Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.49Source | -0.6Source | -0.61Source | -0.51Source | -0.52Source | -0.36Source | -1.87Source | -2.2Source | -2.14Source | -2.62Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 85,732,221Source | 57,262,803Source | 104,453,732Source | 85,497,426Source | 102,800,098Source | 85,426,223Source | 87,006,027Source | 58,743,522Source | 45,247,098Source | 39,995,460Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 85,732,221Source | 57,262,803Source | 104,453,732Source | 85,497,426Source | 102,800,098Source | 85,426,223Source | 87,006,027Source | 58,743,522Source | 45,247,098Source | 39,995,460Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 5,926,000Source | 4,395,000Source | 9,394,000Source | 3,962,000Source | 8,754,000Source | 4,249,000Source | 21,001,000Source | 17,741,000Source | 18,821,000Source | 24,714,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -164,215,000Source | — | — | — |
| Investment Income, InterestUSD | — | — | 3,648,000Source | 2,928,000Source | 4,507,000Source | 4,042,000Source | 4,776,000Source | 4,524,000Source | 16,224,000Source | 12,682,000Source | 8,325,000Source | 2,228,000Source |
| Nonoperating Income (Expense)USD | — | — | 3,660,000Source | 3,066,000Source | 3,979,000Source | 4,080,000Source | 4,897,000Source | 4,484,000Source | 16,247,000Source | 12,784,000Source | 8,306,000Source | 2,201,000Source |
| Operating ExpensesUSD | — | — | 45,877,000Source | 37,621,000Source | 67,179,000Source | 47,864,000Source | 57,986,000Source | 34,873,000Source | 178,698,000Source | 142,258,000Source | 104,961,000Source | 106,988,000Source |
| Research and Development ExpenseUSD | — | — | 39,951,000Source | 33,226,000Source | 57,785,000Source | 43,902,000Source | 49,232,000Source | 30,624,000Source | 157,697,000Source | 124,517,000Source | 86,140,000Source | 82,274,000Source |
Filing attachments
olma-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 3 olma-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer SAN FRANCISCO, August 13, 2026 (Globe NewsWire) - Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the appointment of Jason O’Byrne, MBA, as Chief Financial Officer. “We are ve…
Read attachment ↗olma-ex99_1.htm · 8-K · 2026-08-10
EX-99.1 2 olma-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Olema Oncology Reports Second Quarter 2026 Financial and Operating Results • Completed enrollment in the pivotal Phase 3 OPERA-01 trial; top-line data are now expected in the first quarter of 2027 • Presented initial Phase 1 clinical data for OP-3136 at the 2026 ASCO Annual Meeting • Announced a clinical trial collaboration and supply agreement with Bayer to evaluate darolutamide in combination with OP-3136 in metastatic castration-…
Read attachment ↗olma-ex99_1.htm · 8-K · 2026-05-26
EX-99.1 2 olma-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer • Study to evaluate OP-3136, Olema’s novel KAT6 inhibitor, in combination with darolutamide in approximately 36 patients; expected to initiate in H2 2026 • First clinical collaboration for OP-3136; results to inform combination strategy …
Read attachment ↗olma-ex99_1.htm · 8-K · 2026-05-21
EX-99.1 2 olma-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting • OP-3136 monotherapy was well-tolerated with no dose-limiting toxicities observed and no discontinuations due to treatment-related adverse events • OP-3136 shows evidence of anti-tumor activity across multiple solid tumor types • Data support the ongoing Phase 1 evaluation of OP-3136 as a monot…
Read attachment ↗olma-ex99_1.htm · 8-K · 2026-05-12
EX-99.1 2 olma-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Olema Oncology Reports First Quarter 2026 Financial and Operating Results • Top-line data from the Phase 3 OPERA-01 trial anticipated this fall; Phase 3 OPERA-02 trial continues to enroll patients • First clinical data from OP-3136 Phase 1 study to be presented at ASCO • Ended the first quarter with $505.3 million in cash, cash equivalents, and marketable securities SAN FRANCISCO, May 12, 2026 (Globe NewsWire) - Olema Pharmaceutica…
Read attachment ↗olma-ex99_1.htm · 8-K · 2026-04-29
EX-99.1 2 olma-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Olema Oncology Appoints Prakash Raman, Ph. D., to Board of Directors SAN FRANCISCO, April 29, 2026 (GlobeNewswire) - Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the appointment of Prakash Raman, Ph. D., to its Board of Directors. “We ar…
Read attachment ↗